Alkermes (ALKS) Misses Q2 EPS by 13c, Post FY11 Guidance
Tweet
Share
E-mailGet Alerts ALKS Hot Sheet
Price: $48.07 +4.45%
EPS Growth %: -101.9%
Financial Fact:
Total revenues: 38.5M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -101.9%
Financial Fact:
Total revenues: 38.5M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Alkermes (NASDAQ: ALKS) reported Q2 EPS of ($0.22), $0.13 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $67.71 million.
Alkermes sees FY2012 EPS of $-0.89-$-0.78, versus prior guidance of $-0.47-$0.38 and the consensus of $-0.21. Alkermes sees FY2012 revenue of $350-$380 million, versus prior guidance of $205-$229 million and the consensus of $377.32 million.
Alkermes sees FY2012 EPS of $-0.89-$-0.78, versus prior guidance of $-0.47-$0.38 and the consensus of $-0.21. Alkermes sees FY2012 revenue of $350-$380 million, versus prior guidance of $205-$229 million and the consensus of $377.32 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- AeroVironment restates quarterly financials, citing $89M goodwill error
- Alkermes narcolepsy drug meets phase 2 trial endpoints
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
